Potential role of fecal microbiota in patients with constipation
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Tian Y, Zuo L, Guo Q, Li J, Hu Z, Zhao K, Li C, Li X, Zhou J, Zhou Y, Li XA
Journal
Therapeutic advances in gastroenterology
Year
2020
Keywords:
chronic functional constipation, fecal microbiota transplantation, gastrointestinal motility, intestinal flora
BACKGROUND: We evaluated the safety and efficacy of fecal microbiota transplantation (FMT) for chronic functional constipation (CFC) ineffectively treated by conventional constipation medication. METHODS: Thirty-four patients with CFC underwent FMT treatment (three rounds, via gastroscopy). Clinical scales, including the Wexner constipation score as the main index of efficiency, were completed at baseline; after each treatment, and at 2 and 3 months of follow up. Secondary evaluation indices included the self-assessment of constipation symptoms, patient assessment constipation quality-of-life questionnaire, Bristol stool form scale, and Zung's self-rating depression and anxiety scales. Gastrointestinal motility, motilin, gastrin, nitric oxide (NO), and 5-hydroxytryptamine (5-HT) were assessed before and after treatment. Intestinal flora changes were assessed by 16S ribosomal ribonucleic acid (rRNA) sequencing. RESULTS: There were no serious adverse reactions. The clinical cure rate was 73.5% (25/34), clinical remission rate was 14.7% (5/34), and the inefficiency rate was 11.8% (4/34). Clinical scale data indicated that the FMT treatment was effective. Furthermore, FMT treatment promoted intestinal peristalsis, increased gastrointestinal motility, and increased serum NO and 5-HT levels. The 16S rRNA sequencing data indicated that high abundances of Bacteroides, Klebsiella, Megamonas, Erysipelotrichaceae and Epulopiscium may be the cause of constipation, and high abundances of Prevotella, Acidaminococcus and Butyricimonas may be the main factors in curing constipation. CONCLUSION: Treatment with FMT regulates the intestinal microflora and changes the abundance of CFC-associated bacterial flora to improve constipation.
Experiment 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Transplant outcome measurement Transplant outcome measurement,transplant outcome measurement
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Donor
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- The donors were healthy individuals without diseases or pathologic conditions potentially associated with changes in the gut microbiota.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 34
- Group 1 sample size Number of subjects in the case (exposed) group
- 4
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 1 month
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Donor versus Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in Donor
| NCBI | Quality Control | Links |
|---|---|---|
| Xanthobacteraceae | ||
| Asticcacaulis | ||
| Faecalibacterium | ||
| Dorea | ||
| Blautia | ||
| Anaerostipes | ||
| Lachnospiraceae | ||
| Oscillospiraceae |
Revision editor(s): MyleeeA
Experiment 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Before treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation before Fecal microbiota transplantation treatment.
- Group 0 sample size Number of subjects in the control (unexposed) group
- Not specified
- Group 1 sample size Number of subjects in the case (exposed) group
- Not specified
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between Before treatment versus Donor, After 1st treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in Before treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Phascolarctobacterium | ||
| Bacteroides |
Revision editor(s): MyleeeA
Experiment 3
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 1st treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after first treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 1st treatment versus Donor, Before treatment, After 2nd treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in After 1st treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Odoribacter |
Revision editor(s): MyleeeA
Experiment 4
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 2nd treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after second treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 2nd treatment versus Donor, Before treatment, After 1st treatment, After 3rd treatment, 2 month follow-up and 3 month follow up.
Abundance in Group 1: increased abundance in After 2nd treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Bilophila |
Revision editor(s): MyleeeA
Experiment 5
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- After 3rd treatment
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after third treatment with Fecal microbiota transplantation.
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between After 3rd treatment versus Donor, Before treatment, After 1st treatment, After 2nd treatment, 2-month follow up and 3-month follow up.
Abundance in Group 1: increased abundance in After 3rd treatment
| NCBI | Quality Control | Links |
|---|---|---|
| Dialister | ||
| Megamonas |
Revision editor(s): Anne-mariesharp
Experiment 6
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- 2-month follow up
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 2-months of follow up
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 2-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 3-month follow up.
Abundance in Group 1: increased abundance in 2-month follow up
| NCBI | Quality Control | Links |
|---|---|---|
| Acidaminococcus | ||
| Butyricimonas |
Revision editor(s): Anne-mariesharp
Experiment 7
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- 3-month follow up
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Patients with chronic functional constipation after treatment with Fecal microbiota transplantation and at 3-months of follow up
Lab analysis
Statistical Analysis
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 5
Description: Linear discriminant analysis effect size (LEfSe) analysis of microbial abundance between 3-month follow up versus Donor, Before treatment, After 1st treatment, After 2nd treatment, After 3rd treatment and 2-month follow up.
Abundance in Group 1: increased abundance in 3-month follow up
| NCBI | Quality Control | Links |
|---|---|---|
| Acinetobacter | ||
| Desulfobulbaceae | ||
| Geodermatophilus | ||
| Kingella | ||
| Luteimonas | ||
| Pleomorphomonas | ||
| Synechococcus | ||
| Thalassospira | ||
| Xenococcaceae | ||
| ASSO_13ASSO_13 | ||
| mle1_48mle1_48 |
Revision editor(s): Anne-mariesharp
Retrieved from "https://bugsigdb.org/w/index.php?title=33193813&oldid=203158"
